Pharmaceuticals

Breakthrough therapy designation: From serious diseases to opioid crisis prevention

By , and 2022-10-31T14:41:00

AdobeStock_424041822 (1) [Converted]

Source: Adobe Stock

Following the human immunodeficiency virus crisis of the 1980s, the US Congress and US Food and Drug Administration (FDA) introduced several regulatory initiatives. The purpose was to expedite FDA review and approval of products to overcome the longer traditional pathway review timelines. One such process enabling faster approval is the ...

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

REGISTER FOR FREE

1.

Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

  • Create your own library to save your favourite content.
  • Sign up for Regulatory Rapporteur email newsletters.
Create a free account

Members login

2.

Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.

Login

JOIN TOPRA

3.

TOPRA membership

Become a TOPRA member and join our global regulatory affairs community.

  • Great savings on our events and training.
  • Be part of our dynamic international community.
  • Contribute to the profession.
  • Grow your skills and knowledge.
  • Take your career to the next level.
Become a member